期刊
FEBS JOURNAL
卷 287, 期 16, 页码 3579-3599出版社
WILEY
DOI: 10.1111/febs.15220
关键词
anticancer drug; aspartate transcarbamoylase; drug screening; enzyme mechanism; molecular dynamics
资金
- National Natural Science Foundation of China [21773014]
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2018-04427]
Aspartate transcarbamoylase (ATCase) is a key enzyme which regulates and catalyzes the second step of de novo pyrimidine synthesis in all organisms. Escherichia coli ATCase is a prototypic enzyme regulated by both product feedback and substrate cooperativity, whereas human ATCase is a potential anticancer target. Through structural and biochemical analyses, we revealed that R167/130's loop region in ATCase serves as a gatekeeper for the active site, playing a new and unappreciated regulatory role in the catalytic cycle of ATCase. Based on virtual compound screening simultaneously targeting the new regulatory region and active site of human ATCase, two compounds were identified to exhibit strong inhibition of ATCase activity, proliferation of multiple cancer cell lines, and growth of xenograft tumors. Our work has not only revealed a previously unknown regulatory region of ATCase that helps uncover the catalytic and regulatory mechanism of ATCase, but also successfully guided the identification of new ATCase inhibitors for anticancer drug development using a dual-targeting strategy. Database Structure data are available in Protein Data Bank under the accession numbers: (G166P ecATCase), (G166P ecATCase-holo), (G128/130A ecATCase), and (G128/130A ecATCase-holo).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据